Restoring Life's Potential
with Innovative Solutions for the Treatment of Nerve Damage
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage.
NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration, remyelination and plasticity. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various indications.
NVG-291 is expected to enter Phase 1 clinical trials in the first half of 2021.
Our technology was developed in the laboratory of Dr. Jerry Silver, a renowned spinal cord injury and regenerative medicine researcher and Professor of Neurosciences at Case Western Reserve University (CWRU) in Cleveland, Ohio.
Dr. Silver’s research focuses on the glial scar which forms at sites of a physical injury such as spinal cord injury, as well as sites of inflammatory damage from neurodegenerative diseases.
Dr. Silver and his collaborators were able to discover a constituent in scars that is a major inhibitor of the body’s natural ability to regrow and regenerate, and the key neural receptor that binds to the constituent to inhibit nerve regeneration, known as protein tyrosine phosphatase sigma (PTPσ).